Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
16.9 SEK | +2.67% | +7.10% | +9.31% |
Apr. 17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
Apr. 17 | Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.31% | 53.01M | |
+3.37% | 69.25B | |
+12.55% | 9B | |
-12.75% | 4.96B | |
+42.38% | 4.47B | |
+5.23% | 3.9B | |
+19.92% | 2.45B | |
-19.05% | 2.41B | |
-28.72% | 2.23B | |
+11.13% | 2.02B |
- Stock Market
- Equities
- ORX Stock
- News Orexo AB
- Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment